01952 EVEREST MED-B
- 35.150
- +0.350+1.01%
EVEREST MED-B News
Cloud Top New Glory-B (01952.HK) appoints Ernst & Young as auditors.
On November 15, Gelonghui reported that Genting New Year-B (01952.HK) announced that, since the company could not reach an agreement with RSM on the auditor's remuneration for the fiscal year ending December 31, 2024, to enhance the cost-effectiveness of the company's annual audit and to maintain good corporate governance, the board of directors has notified RSM of the proposal to replace the auditor, and RSM has agreed to resign as the company's auditor, effective November 15, 2024. The board of directors, under the recommendation of the audit committee, has resolved to appoint Ernst & Young as the new auditor of the company, effective November 15, 2024.
Express News | Yunding Xinyao Nai Fukang Global Open Label Extension Research Announcement.
Cloud Top Nova-B (01952) recently continuously released heavy research data and made key progress, the domestic market is expected to enter a period of outbreak.
Recently, Hong Kong-listed innovative drug company YunDing XinYao-B (01952) released a blockbuster product - the world's first IgA nephropathy targeted therapy drug Nefecon (budesonide enteric capsules) NefIgArd Phase III clinical trial global open-label extension (OLE) study, announcing positive data at the American Society of Nephrology (ASN) Kidney Week 2024.
The Yunding Xin Yao announces the positive results of the extension study of the second treatment course of Phase III trial of Nephacan, providing new evidence for long-term treatment strategy for IgA nephropathy.
Genting Bio-Pharma (HKEX 1952.HK) is a biopharmaceutical company focused on the research and development, clinical development, manufacturing, and commercialization of innovative drugs, today announced the results of the open-label extension (OLE) study of the global Phase III clinical trial NefIgArd of Nefcourant (budesonide enteric capsules, NEFECON) will be presented at the 2024 American Society of Nephrology (ASN).
This week, Hong Kong stocks' star stocks | Expectations of top brokerages merging are hyped! A-share trading is hot! China-affiliated brokerage stocks collectively soaring; shanghai electric group skyrocketed by 62% in one week, officially announcing merg
This week, the Hong Kong stock market ended four consecutive weeks of decline, with daily levels still fluctuating. The Hang Seng Index rose by 1.08% to 20,728.19 points; during the same period, the Hang Seng Tech Index rose by 4.11% to 4,668.26 points; the Hang Seng China Enterprises Index rose by 1.62% to 7,461.44 points.
Hong Kong stock market retreats from its high levels, with the Hang Seng Index and the H-share Index both falling by over 1%; the real estate and brokerage sectors decline, Sunac drops more than 9%, Citic Securities falls by nearly 6%.
Network technology stocks decline, NetEase-S drops by 5.61%, Meituan-W drops by 4.05%; Securities and brokerage stocks weaken, CSC drops by 5.45%, China International Capital Corporation drops by 4.34%; Coal industrial concept stocks weaken, China Coal Energy drops by 4.22%, Kinetic Dev drops by 3.18%.
Bocom Intl: The tenth batch of national procurement starts with reported volumes. Bullish on sector sentiment improvement + valuation recovery after medical insurance negotiations land.
bocom intl highly recommends akeso (09926), simcere pharma (02096), legend biotech (LEGN.US), silver crest new yaobin-B (01952), and hutchmed (china) (00013), etc.
HK Stock Market Update | Genting Hong Kong -B (01952) surged more than 8% in the afternoon. National medical insurance negotiations have ended, institutions bullish on innovative varieties being included in medical insurance for increased trading volume.
Genting New Star-B (01952) rose more than 8% in the afternoon, as of the time of publication, up 6.94% to HK$33.15, with a turnover of 0.195 billion Hong Kong dollars.
Express News | The results of the national medical insurance negotiations are expected to be released at the end of November 2024.
HK Stocks Movement | Genting Hong Kong Limited (01952) surged nearly 5%, Novozymes added another major bullish news, commercialization expectations are expected to rise.
Genting NewStar-B (01952) rose nearly 5% in early trading, up 2.11% as of the time of publication, trading at 31.5 Hong Kong dollars, with a turnover of 49.5448 million Hong Kong dollars.
Hong Kong stocks are active | Some pharmaceutical stocks rose in early trading, as the national medical insurance negotiations are expected to start soon. Institutions stated that there will be a high concentration of catalytic events in the sector in the
Some pharmaceutical stocks rose in the morning session. As of the time of publication, Remegen (09995) rose by 8.73% to HKD 15.7; SciClone Pharmaceuticals-B (02171) rose by 6.47% to HKD 15.7; Sino Biopharmaceutical-B (01952) rose by 2.11% to HKD 31.5; Fosun Pharma (02196) rose by 3.7% to HKD 15.12.
Express News | In 2024, the national negotiations in the afternoon include multiple psychiatric drugs and orphan drugs, jiangsu hengrui pharmaceuticals, and humanwell healthcare products.
Stock market bullish this week | Continuous bullish news in the solar industry! GCL Tech surged 50% weekly; its siasun robot&automation entered multiple auto companies, UBTech rose more than 30%
This week, the Hang Seng Index fell by 1.03% to 20,590.15 points; during the same period, the Hang Seng Tech Index fell by 1.37% to 4,538.03 points; the Hang Seng China Enterprises Index fell by 1.16% to 7,385.26 points during the same period.
Bocom Intl: Guangzhou launches first batch of innovative drugs and medical devices catalog, focusing on innovation and consumer properties as symbols.
Following the introduction of multiple policies encouraging the innovation of pharmaceuticals, the latest innovative drug and medical device catalog released by Guangzhou will further provide full-chain, all-field support for the high-quality development of the biomedical industry.
Genting New Excelsior (01952.HK) has obtained approval for the urgent import of pharmaceutical products from the Mainland of the Greater Bay Area to Hong Kong and Macau.
Genting New Glow (01952.HK) announced that, under the 'Hong Kong-Macau Pharmaceutical Machinery Passage' policy support, VELSIPITY has officially obtained approval for the import of medical products urgently needed in the Greater Bay Area of Guangdong, Hong Kong, and Macau. It can be used in Foshan Fosun Chensheng Hospital and The First Affiliated Hospital of Sun Yat-sen University, two medical institutions designated under the Greater Bay Area medical machinery passage policy, for the treatment of ulcerative colitis (UC) patients aged 16 and above with moderate to severe activity. The company expects that VELSIPITY will gradually be introduced into other qualified medical institutions under the pharmaceutical machinery passage. Dennis Law, CEO of Genting New Glow, stated that the official landing of VELSIPITY in the Greater Bay Area is
Genting Luminous (01952) announced that VELSIPITY has been approved to enter the south china greater bay area concept, bringing new choices for ulcerative colitis patients.
Sino Biopharmaceutical (01952) is a biopharmaceutical company focused on the research and development, clinical development, manufacturing, and commercialization of innovative drugs.
Stock Market Update | Genting New York-B (01952) rose more than 4% against the market trend, with two recent positive developments related to Nephrocang.
Genting New Glory-B (01952) rose more than 4% against the market, as of the deadline, up 4.41% to HK$36.7, with a turnover of 83.067 million Hong Kong dollars.
YunDing XinYao-B: Nafolkang is the world's first immunoglobulin A nephropathy treatment drug to receive full FDA approval.
Genting New Star-B (01952) announced two exciting latest developments about Nephcure, the first and only pharmaceutical approved by the US Food and Drug Administration for the treatment of immunoglobulin A nephropathy (IgA nephropathy) globally.
Hong Kong stock innovative drugs sector once again welcomes national market sentiment, with "real innovation" becoming a key layout.
For domestic innovative drug enterprises, the medical insurance catalog has now become a 'threshold'. As long as the innovative drug enterprises successfully cross the threshold, they can rely on the logic of trading price for quantity to achieve rapid volume expansion of products, thereby crossing a major step in the company's cash realization speed and hematopoietic ability.
Hong Kong stock market midday review | The three major indices are all rising! The technology index rose more than 1%, with autos and nuclear power leading the gains, li auto inc rose more than 7%, cgn mining surged more than 21%.
Network technology stocks rose across the board, with Sensetime-W up 4.40%, Meituan-W up 3.75%; digital health stocks performed well, with Mindray Medical up 15.28%, jd health up 3.99%; securities and brokerage stocks rallied, china merchants rose 5.13%, swhy rose 4.74%.
Analysis
Price Target
No Data
No Data